This topic contains a solution. Click here to go to the answer

Author Question: A nurse is caring for a client with urinary retention who is receiving a cholinergic drug as part of ... (Read 64 times)

crazycityslicker

  • Hero Member
  • *****
  • Posts: 537
A nurse is caring for a client with urinary retention who is receiving a cholinergic drug as part of the treatment plan. After administering the drug, the nurse would notify the primary health care provider
 
  if the assessment reveals which of the following?
 
  A) Failure to void after drug administration
  B) Frequent vomiting after drug administration
  C) Increase in abdominal pain after drug administration
  D) Occurrence of blood in urine after drug administration

Question 2

A nurse is caring for a client with urinary retention who is prescribed bethanechol. The nurse would administer this drug cautiously if the client has which of the following?
 
  A) Raynaud's disease
  B) Bradycardia
  C) Coronary artery disease
  D) Hyperthyroidism



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

swimkari

  • Sr. Member
  • ****
  • Posts: 332
Answer to Question 1

Ans: A
Feedback:
The nurse should notify the primary health care provider if the client fails to void after drug administration. Frequent vomiting, increase in abdominal pain, and occurrence of blood in urine are not usually observed when urinary retention is treated with cholinergic therapy.

Answer to Question 2

Ans: B
Feedback:
The nurse should administer bethanechol cautiously if a client has bradycardia, hypertension, epilepsy, cardiac arrhythmias, recent coronary occlusion, or megacolon. Cautious use is not necessary if the client has Raynaud's disease, coronary artery disease, or hyperthyroidism.




crazycityslicker

  • Member
  • Posts: 537
Reply 2 on: Jul 23, 2018
Great answer, keep it coming :)


bbburns21

  • Member
  • Posts: 336
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

Did you know?

Blood in the urine can be a sign of a kidney stone, glomerulonephritis, or other kidney problems.

Did you know?

Looking at the sun may not only cause headache and distort your vision temporarily, but it can also cause permanent eye damage. Any exposure to sunlight adds to the cumulative effects of ultraviolet (UV) radiation on your eyes. UV exposure has been linked to eye disorders such as macular degeneration, solar retinitis, and corneal dystrophies.

Did you know?

Cutaneous mucormycosis is a rare fungal infection that has been fatal in at least 29% of cases, and in as many as 83% of cases, depending on the patient's health prior to infection. It has occurred often after natural disasters such as tornados, and early treatment is essential.

Did you know?

Intradermal injections are somewhat difficult to correctly administer because the skin layers are so thin that it is easy to accidentally punch through to the deeper subcutaneous layer.

For a complete list of videos, visit our video library